tradingkey.logo

HeartSciences Inc

HSCS
查看详细走势图
2.580USD
-0.060-2.27%
收盘 12/24, 13:00美东报价延迟15分钟
7.92M总市值
亏损市盈率 TTM

HeartSciences Inc

2.580
-0.060-2.27%
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

-2.27%

5天

+16.74%

1月

+1.98%

6月

-32.64%

今年开始到现在

-32.46%

1年

-30.05%

查看详细走势图

TradingKey HeartSciences Inc股票评分

单位: USD 更新时间: 2025-12-24

操作建议

HeartSciences Inc当前公司基本面数据相对稳定,增长潜力较大。当前估值合理,在医疗设备与耗材行业排名143/206位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价13.50。中期看,股价处于下降通道。近一个月,市场表现一般,基本面和技术面综合得分也较低。目前股价在压力位和支撑位之间,可以做区间波段操作。

HeartSciences Inc评分

相关信息

行业排名
143 / 206
全市场排名
389 / 4562
所属行业
医疗设备与耗材

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

分析师目标

根据 2 位分析师
买入
评级
13.500
目标均价
+363.92%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

HeartSciences Inc亮点

亮点风险
HeartSciences Inc. is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. The Company has libraries of artificial intelligence-enhanced electrocardiography (AI-ECG) algorithms and is developing AI-ECG solutions to be made available on either a hardware- agnostic cloud-based platform or its proprietary MyoVista wavECG device, to help identify cardiovascular disease in any care setting worldwide in a manner to suit different care providers. Its first product candidate for FDA clearance, the MyoVista wavECG, or the MyoVista, is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction, which has traditionally only been available through the use of cardiac imaging. The MyoVista also provides conventional ECG information in the same test. It delivers AI-ECG algorithms using existing ECG devices across a hospital or health system.
业绩增长期
公司处于发展阶段,最新年度总收入4.35K美元
利润高增长
公司净利润处于行业前列,最新年度总收入4.35K美元
估值合理
公司最新PE估值-0.39,处于3年历史合理位
机构加仓
最新机构持股108.58K股,环比增加31.39%
先锋集团持仓
明星投资者先锋集团持仓,最新持仓市值18.56K

HeartSciences Inc新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

HeartSciences Inc简介

HeartSciences Inc. is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. The Company has libraries of artificial intelligence-enhanced electrocardiography (AI-ECG) algorithms and is developing AI-ECG solutions to be made available on either a hardware- agnostic cloud-based platform or its proprietary MyoVista wavECG device, to help identify cardiovascular disease in any care setting worldwide in a manner to suit different care providers. Its first product candidate for FDA clearance, the MyoVista wavECG, or the MyoVista, is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction, which has traditionally only been available through the use of cardiac imaging. The MyoVista also provides conventional ECG information in the same test. It delivers AI-ECG algorithms using existing ECG devices across a hospital or health system.
公司代码HSCS
公司HeartSciences Inc
CEOSimpson (Andrew)
网址https://heartsciences.com/

常见问题

HeartSciences Inc(HSCS)的当前股价是多少?

HeartSciences Inc(HSCS)的当前股价是 2.580。

HeartSciences Inc的股票代码是什么?

HeartSciences Inc的股票代码是HSCS。

HeartSciences Inc股票的52周最高点是多少?

HeartSciences Inc股票的52周最高点是6.470。

HeartSciences Inc股票的52周最低点是多少?

HeartSciences Inc股票的52周最低点是2.010。

HeartSciences Inc的市值是多少?

HeartSciences Inc的市值是7.92M。

HeartSciences Inc的净利润是多少?

HeartSciences Inc的净利润为-8.77M。

现在HeartSciences Inc(HSCS)的股票是买入、持有还是卖出?

根据分析师评级,HeartSciences Inc(HSCS)的总体评级为买入,目标价格为13.500。

HeartSciences Inc(HSCS)股票的每股收益(EPS TTM)是多少

HeartSciences Inc(HSCS)股票的每股收益(EPS TTM)是-6.567。
KeyAI